Noninvasive prenatal screening for cystic fibrosis using circulating trophoblasts: Detection of the 50 most common disease-causing variants

Prenat Diagn. 2023 Jan;43(1):3-13. doi: 10.1002/pd.6276. Epub 2022 Dec 8.

Abstract

Objectives: Cystic fibrosis (CF) is one of the most common severe autosomal recessive disorders. Prenatal or preconception CF screening is offered in some countries. A maternal blood sample in early pregnancy can provide circulating trophoblasts and offers a DNA source for genetic analysis of both the mother and the fetus. This study aimed to develop a cell-based noninvasive prenatal test (NIPT) to screen for the 50 most common CF variants.

Methods: Blood samples were collected from 30 pregnancies undergoing invasive diagnostics and circulating trophoblasts were harvested in 27. Cystic fibrosis testing was conducted using two different methods: by fragment length analysis and by our newly developed NGS-based CF analysis.

Results: In all 27 cases, cell-based NIPT provided a result using both methods in agreement with the invasive test result.

Conclusion: This study shows that cell-based NIPT for CF screening provides a reliable result without the need for partner- and proband samples.

MeSH terms

  • Cystic Fibrosis* / diagnosis
  • Cystic Fibrosis* / genetics
  • Female
  • Fetus
  • Genetic Testing / methods
  • Humans
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Prenatal Diagnosis / methods
  • Trophoblasts